For informational purposes only — not investment advice

← Back to signals

ANGO

INSIDER SELL

AngioDynamics, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
2.9d↑+54.7%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Positive

AngioDynamics reaffirmed FY2027 guidance with MedTech expected to become majority revenue (12–15% growth driven by Auryon, thrombectomy, and NanoKnife), while advancing NanoKnife IRE clinical outcomes and reimbursement access. New CEO Eric Honroth commenced November 2, 2026, with predecessor Jim Clemmer remaining involved in transition, supporting continuity of the portfolio transformation strategy.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Trowbridge Stephen AEVP and CFOSELL24K$12.27$0.29M2026-10-29↗
Trowbridge Stephen AEVP and CFOSELL2K$12.17$0.02M2026-10-28↗

Fund 13D/13G Filings (2)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Point72SC 13G/A−2.2M2.3%
-5.4% vs SPY
-8.7% abs
2026-11-16↗
Point72SC 13G/A—7.7%
+39.9% vs SPY
+45.4% abs
2026-05-15↗